Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

20211,680 citationsJournal Articlebronze Open Access

Authors

Toni K. Choueiri · Dana-Farber Cancer Institute

Thomas Powles · National Health Service

Mauricio Burotto

Bernard Escudier · Institut Gustave Roussy

María T. Bourlon · Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Bogdan Żurawski

Víctor Manuel Oyervides-Juárez · Hospital Universitario Dr José Eleuterio Gonzalez

James J. Hsieh

Abstract

Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol Myers Squibb and others; CheckMate 9ER ClinicalTrials.gov number, NCT03141177.).

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 9, pp. 829-841

DOI: 10.1056/nejmoa2026982

Field-Weighted Citation Impact: 195.97